<p>(A) Viability of the cells treated with different concentrations of TRAIL or DR5-B during 8, 16, 20 and 24 h of incubation. (B) Viability of the cells treated with 1 nM bortezomib and different concentrations of TRAIL or DR5-B during 8, 16, 20 and 24 h of incubation. (C) Cells were incubated with different concentrations of bortezomib and cell death was measured after 24 h of incubation. (D) Calculation of effective concentrations of TRAIL variants after 24 h treatment of cells with 1 nM bortezomib. Values are mean ± SD of at least three independent experiments.</p
<p>(A) DR4 and DR5 receptors cell surface expression was analyzed in HCT116 p53<sup>−/−</sup> cells ...
TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) mediates apoptosis in cancer cells t...
<p>Cell viability measurements (CellTiter-Glo) on NB7 cells treated with A) 1 µM APDC (Ammonium pyrr...
<p>In all experiments, cells were treated with 1 nM bortezomib and 1 ng/ml TRAIL variants alone or i...
<p>(A) DR4 and DR5 receptors cell surface expression was analyzed after incubation of the cells with...
<p>(A) Time- and dose–response curves of HHT from 0.01 nM to 1000 nM. (B) Time- and dose–response cu...
Figure S3. Cell death inducing ability of bortezomib was analyzed in TRAIL-resistant cells. Four TRA...
<p>(A). Frequency of apoptosis of RPMI 8226 and AMO1. Left panels: dot plots showing the frequency o...
<p>(A) Dose-response curve of bortezomib sensitivity in representative cell lines. The vertical axis...
<p>HCT116 p53<sup>+/+</sup> (A) and HCT116 p53<sup>−/−</sup> (B) cells were treated with TRAIL (1 ng...
Abstract Background Multiple trials have attempted to demonstrate the effective induction of cell de...
<p>(A) SKM-1 cells treated with 46.20 nM HHT, 4.46 nM Bortezomib or 46.20 nM HHT + 4.46 nM Bortezomi...
<p>A,B: HEK293T cells were treated for 1 hour with the indicated concentration of bortezomib. Peptid...
<p>DR4 receptor cell surface expression and viability of the HCT116 p53<sup>+/+</sup> cells were ana...
<p>A) U87MG cells were seeded in a 96-well plate at a density of 10,000 cells per well. Cells were e...
<p>(A) DR4 and DR5 receptors cell surface expression was analyzed in HCT116 p53<sup>−/−</sup> cells ...
TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) mediates apoptosis in cancer cells t...
<p>Cell viability measurements (CellTiter-Glo) on NB7 cells treated with A) 1 µM APDC (Ammonium pyrr...
<p>In all experiments, cells were treated with 1 nM bortezomib and 1 ng/ml TRAIL variants alone or i...
<p>(A) DR4 and DR5 receptors cell surface expression was analyzed after incubation of the cells with...
<p>(A) Time- and dose–response curves of HHT from 0.01 nM to 1000 nM. (B) Time- and dose–response cu...
Figure S3. Cell death inducing ability of bortezomib was analyzed in TRAIL-resistant cells. Four TRA...
<p>(A). Frequency of apoptosis of RPMI 8226 and AMO1. Left panels: dot plots showing the frequency o...
<p>(A) Dose-response curve of bortezomib sensitivity in representative cell lines. The vertical axis...
<p>HCT116 p53<sup>+/+</sup> (A) and HCT116 p53<sup>−/−</sup> (B) cells were treated with TRAIL (1 ng...
Abstract Background Multiple trials have attempted to demonstrate the effective induction of cell de...
<p>(A) SKM-1 cells treated with 46.20 nM HHT, 4.46 nM Bortezomib or 46.20 nM HHT + 4.46 nM Bortezomi...
<p>A,B: HEK293T cells were treated for 1 hour with the indicated concentration of bortezomib. Peptid...
<p>DR4 receptor cell surface expression and viability of the HCT116 p53<sup>+/+</sup> cells were ana...
<p>A) U87MG cells were seeded in a 96-well plate at a density of 10,000 cells per well. Cells were e...
<p>(A) DR4 and DR5 receptors cell surface expression was analyzed in HCT116 p53<sup>−/−</sup> cells ...
TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) mediates apoptosis in cancer cells t...
<p>Cell viability measurements (CellTiter-Glo) on NB7 cells treated with A) 1 µM APDC (Ammonium pyrr...